BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 18951468)

  • 21. Triptolide inhibits Bcr-Abl transcription and induces apoptosis in STI571-resistant chronic myelogenous leukemia cells harboring T315I mutation.
    Shi X; Jin Y; Cheng C; Zhang H; Zou W; Zheng Q; Lu Z; Chen Q; Lai Y; Pan J
    Clin Cancer Res; 2009 Mar; 15(5):1686-97. PubMed ID: 19240172
    [TBL] [Abstract][Full Text] [Related]  

  • 22. JAK2 mutation and atypical chronic myeloid leukemia.
    Campiotti L; Uccella S; Appio L; Pallotti F; La Rosa S; Capella C; Venco A
    Leuk Res; 2009 Sep; 33(9):e166-7. PubMed ID: 19427035
    [No Abstract]   [Full Text] [Related]  

  • 23. Tumor lysis syndrome after starting treatment with Gleevec in a patient with chronic myelogenous leukemia.
    Al-Kali A; Farooq S; Tfayli A
    J Clin Pharm Ther; 2009 Oct; 34(5):607-10. PubMed ID: 19744017
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The myeloproliferative neoplasm-associated JAK2 46/1 haplotype is not overrepresented in chronic myelogenous leukemia.
    Spolverini A; Jones AV; Hochhaus A; Pieri L; Cross NC; Vannucchi AM
    Ann Hematol; 2011 Mar; 90(3):365-6. PubMed ID: 20556390
    [No Abstract]   [Full Text] [Related]  

  • 25. Philadelphia chromosome positive myelodysplastic syndrome and acute myelogenous leukemia.
    Advani AS
    Leuk Res; 2004 Jun; 28(6):545-6. PubMed ID: 15120928
    [No Abstract]   [Full Text] [Related]  

  • 26. Exfoliative dermatitis with leukemia cutis in a patient with chronic myeloid leukemia: a rare association.
    Raj A; Rai R; Rangarajan B
    Indian J Dermatol Venereol Leprol; 2011; 77(2):208-10. PubMed ID: 21393960
    [No Abstract]   [Full Text] [Related]  

  • 27. [Leukemias in advanced age. Part 2: Myelodysplastic syndrome and chronic leukemia].
    Jehn U
    Fortschr Med; 1994 May; 112(13):180-4. PubMed ID: 8020858
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Circumventing resistance to imatinib therapy in chronic myeloid leukemia].
    Minami Y; Naoe T
    Gan To Kagaku Ryoho; 2009 Apr; 36(4):544-7. PubMed ID: 19381024
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Resolution of rheumatoid arthritis symptoms with imatinib mesylate.
    Vernon MR; Pearson L; Atallah E
    J Clin Rheumatol; 2009 Aug; 15(5):267. PubMed ID: 19654496
    [No Abstract]   [Full Text] [Related]  

  • 30. Concurrent JAK2-Positive Myeloproliferative Disorder and Chronic Myelogenous Leukemia: A Novel Entity? A Case Report With Review of the Literature.
    Bader G; Dreiling B
    J Investig Med High Impact Case Rep; 2019; 7():2324709619832322. PubMed ID: 30803277
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Molecular response to imatinib in patient with Ph negative p190 BCR-ABL transcript positive chronic myeloid leukemia with cyclic leukocytosis.
    Radojkovic M; Ristic S; Pavlovic S; Colovic M
    Leuk Res; 2009 Jun; 33(6):e10-2. PubMed ID: 19091403
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Erythroid variant of chronic myelogenous leukemia.
    Talreja N; Abdulhaq H; Shadduck RK; Rossetti J; Jalil A; Makary A; Lister J
    Leukemia; 2008 Apr; 22(4):867-70. PubMed ID: 18033324
    [No Abstract]   [Full Text] [Related]  

  • 33. JAK2 V617F mutation is associated with 5q- syndrome in Chinese.
    Wong KF; Wong WS; Siu LL; Lau TC; Chan NP
    Leuk Lymphoma; 2009 Aug; 50(8):1333-5. PubMed ID: 19562618
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A 51-year-old male CML patient with progressive hearing loss, confusion, ataxia, and aphasia during imatinib treatment.
    Janssen JJ; Berendse HW; Schuurhuis GJ; Merle PA; Ossenkoppele GJ
    Am J Hematol; 2009 Oct; 84(10):679-82. PubMed ID: 19658186
    [No Abstract]   [Full Text] [Related]  

  • 35. Chronic myelogenous leukemia with the e6a2 BCR-ABL and lacking imatinib response: presentation of two cases.
    Vefring HK; Gruber FX; Wee L; Hovland R; Hjorth-Hansen H; Gedde Dahl T; Meyer P
    Acta Haematol; 2009; 122(1):11-6. PubMed ID: 19641300
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Specific assessment of BCR-ABL transcript overexpression and imatinib resistance in chronic myeloid leukemia patients.
    Bianchini M; De Brasi C; Gargallo P; Gonzalez M; Bengió R; Larripa I
    Eur J Haematol; 2009 Apr; 82(4):292-300. PubMed ID: 19191867
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Molecular bases of leukemia, MPD and MDS].
    Kitamura T
    Rinsho Ketsueki; 2009 Mar; 50(3):174-81. PubMed ID: 19352084
    [No Abstract]   [Full Text] [Related]  

  • 38. Longstanding remission of adult onset Still's disease under imatinib therapy in a patient with chronic myelogenous leukemia.
    Nagasaki Y; Miyamoto T; Henzan H; Nagafuji K; Harada M; Akashi K
    J Rheumatol; 2009 Jun; 36(6):1349-51. PubMed ID: 19509096
    [No Abstract]   [Full Text] [Related]  

  • 39. Insights into JAK2-V617F mutation in CML.
    Büsche G; Hussein K; Bock O; Kreipe H
    Lancet Oncol; 2007 Oct; 8(10):863-4. PubMed ID: 17913656
    [No Abstract]   [Full Text] [Related]  

  • 40. Donor cell-derived myelodysplastic syndrome in a patient 7 years after unrelated allogeneic HLA-mismatched transplantation for Ph+ chronic myeloid leukemia.
    Kraut L; Trebeljahr G; Thiele B; Fauser AA
    Bone Marrow Transplant; 2005 Oct; 36(8):737. PubMed ID: 16086042
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.